Application and medical application of punicalagin as PTP1B inhibitor

Abstract

The invention relates to application and medical application of punicalagin as a PTP1B inhibitor and further relates to application of punicalagin in preparation of medicine for preventing or treating diseases relevant to protein-tyrosine-phosphatase 1B (PTP1B). Punicalagin serves as a natural active compound in plants and has high success probability in the later research and development process of the medicine.

Description

technical field [0001] The present invention relates to the field of diabetes, in particular to the application of punicalagin as an inhibitor of protein tyrosine phosphatase 1B (PTP1B). Background technique [0002] Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia, which is caused by defective insulin secretion or its biological action, or both. The prevalence of DM is increasing globally. According to the latest statistics from the International Diabetes Federation (IDF), as of 2013, 382 million people around the world suffer from diabetes, and this number is expected to rise to 592 million by 2035. Type 2 diabetes mellitus (T2DM) is the most common form of diabetes, accounting for approximately 90% of diabetes worldwide, and is characterized by hyperglycemia, dyslipidemia, and insulin resistance in metabolic target tissues. Type 2 diabetes can lead to serious complications including kidney failure, blindness, slow wound healing and ...

AI Technical Summary

Problems solved by technology

These synthetic compounds have a good hypoglycemic ef

Images